This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Alván G, Balant LP, Bechtel, PR, Boobis AR, Gram LF and Pithan K (eds) (1990). Proceedings European Consensus Conference on Pharmacogenetics. Commission of the European Communities (Co-ordinated Action COST B1), Luxembourg.
Andersson T, Regardh CG, Lou YC, Zhang Y, Dahl ML and Bertílsson L(1992). Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 2: 25–31.
Balant LP, Gundert-Remy U, Boobis AR and von Bahr Ch (1989). Relevance of genetic polymorphism in drug metabolism in the development of new drugs. Eur J Clin Pharmacol 36: 551–554.
Bertilsson L, Aberg-Wistedt A, Gustafsson LL, Nordin C (1985). Extremely rapid hydroxylation of debrisoquine: a case report with implications for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 7:478–480.
Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J and Villén T (1989). Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquine, hydroxylation phenotype. Clin Pharmacol Ther 45: 348–355.
Bertilsson L, Dahl M-L, Sjögvist F, Asberg-WistedtA, Humble M, Johansson I, Lundquist E and Ingelman-Sundberg M (1993). Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 341: 63.
Breimer, DD (1983). Interindividual variations in drug disposition. Clinical implications and methods of investigation. Clin Pharmacokin 8: 371–377.
Breimer DD (1990). Potential clinical relevance of the interplay between genetic and environmental factors. In: Alván et al. (eds) pp. 69–80.
Breimer DD and Schellens JHM (1990). A “cocktail” strategy to assess in vivo oxidative drug metabolism in humans. Trends Pharmacol Sci 11: 223–225.
Cholerton S, Daly AK and Idle JR (1992). The role of individual human cytochromes P-450 in drug metabolism and clinical response. Trends Pharmacol Sci 13: 434–439.
Dayer P (1990). Advantages and drawbacks of probe drugs for the assessment of the phenotypic expression of cytochrome P-450 DB 1 (P450IID6). In: Alván et al. (eds), pp. 33–42.
Eichelbaum M and Gross AS (1992). The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. In: Kalow W (ed.), pp. 625–648
Eichelbaum M, Spannbrucker N, Steincke B and Dengler HJ (1979). Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16:153.
Gonzalez FJ (1992). Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 13:346–352.
Kalow W (ed.) (1992). Pharmacogenetics of Drug Metabolism. Pergamon Press, New York.
Koymans LMH, Vermeulen NPE, van Acker SABE, te Koppele JM, Heykants JJP, Lavrijsen K, Meuldermans W and Donné-Op den Kelder GM (1992). A predictive model for substrates of cytochrome P-450 debrisoquine (2D6). Chem Res Toxicol 5:211–219.
Küpfer A and Preisig P (1984). Pharmacogenetics of mephenytoin: a new hydroxylation polymorphism in man. Eur J Clin Pharmacol 26:753–759.
La Du BN (1992). Overview of pharmacogenetics. In: Kalow W (ed.), pp. 1–12.
Lennard MS (1992). The polymorphic oxidation of beta-adrenoreceptor antagonists. In: Kalow W (ed.), pp. 701–720.
Mahgoub A, Idle JR, Dring LG, Lancester R and Smith RL (1977). Polymorphic hydroxylation of debrisoquine in man. Lancet 2:584–586.
Meyer UA, Skoda RC, Zanger UM, Heim M and Broly F (1992). The genetic polymorphism of debrisoquine/ sparteine metabolism - molecular mechanisms. In: Kalow W (ed.), pp. 609–623.
Price Evans DA (1992). N-Acetyltransferase. In: Kalow W (ed.), pp. 95–178.
Sjögvist F (1992). Pharmacogenetic factors in the metabolism of tricyclic antidepressants and some neuroleptics. In: Kalow W (ed.), p. 689–700.
Steiner E, Bertilsson L, Säwe J, Bertling I and Sjögvist F (1988). Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 44:431–435.
Tucker GT, Silas JH, Iyun AO, Lennard MS and Smith AJ (1977). Polymorpic hydroxylation of debrisoquine. Lancet 2:718.
Vasko MR, Bell RD, Daly DD and Pippenger CE (1980). Inheritance of phenytoin hypometabolism: a kinetic study of one family. Clin Pharmacol Ther 27:96–103.
Wilkinson GR (1989).Pharmacogenetic factors responsible for variability in drug disposition. In: Breimer DD, Crommelin JJ and Midha KK, (eds) Topics in Pharmaceutical Sciences Fédération Internationale Pharmaceutique, The Hague, pp. 541–554.
Wilkinson GR, Guengerich FP and Branch RA (1992). Genetic polymorphism of S-mephenytoin hydroxylation. In: Kalow W (ed.), p. 657–685
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Breimer, D.D. (1994). Genetic polymorphisms in drug metabolism: clinical implications and consequences in ADME studies. In: Walker, S., Lumley, C., McAuslane, N. (eds) The Relevance of Ethnic Factors in the Clinical Evaluation of Medicines. CMR Workshop Series. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-1420-2_2
Download citation
DOI: https://doi.org/10.1007/978-94-011-1420-2_2
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-4621-3
Online ISBN: 978-94-011-1420-2
eBook Packages: Springer Book Archive